Printer Friendly

Nexell Therapeutics Receives Approval to Market Isolex Cell Selection Systems in the United States.

IRVINE, Calif.--(BUSINESS WIRE)--July 6, 1999--

Only Commercially Available Systems Enter

Expanding Market for Stem Cell Selection

Nexell Therapeutics Inc. (NASDAQ:NEXL) announced today that the U.S. Food and Drug Administration (FDA) has given the Company clearance to market its Isolex(R) Magnetic Cell Selection Systems in the United States.

The semi-automated Isolex(R) 300 and fully-automated Isolex(R) 300i, along with the reagent kit and disposable sets used in each selection procedure, will be sold for the selection of hematopoietic stem cells and the removal of tumor cells from autologous peripheral blood as a component of aggressive cancer treatment.

They are the only stem cell selection systems commercially available in the United States.

"This approval is not only a milestone for Nexell Therapeutics but an important step forward in the application of stem cell selection technology to clinical medicine," said Richard L. Dunning, Chairman and CEO of Nexell Therapeutics Inc. "The United States is the largest and most dynamic market for cell selection in the world. The commercial availability of the Isolex(R) systems in the U.S. will increase access by oncologists and their patients to state-of-the-art transplantation techniques, while giving researchers the technological platform to explore new frontiers in cell therapy."

The launch of the Isolex(R) systems will take place over the next several months and initially focus on the conversion of existing Isolex(R) investigational sites to commercial status and the installation of Isolex(R) systems at sites currently operating CellPro Ceprate SC devices.

These sites have continued to use the Ceprate SC system under a limited supply agreement with Baxter Healthcare Corporation created to provide treatment for patients in need of stem cell selection in the interim between cessation of CellPro's business operations and Isolex(R) approval.

Growth in Stem Cell Selection

Stem cell transplantation is currently performed after high-dose chemotherapy (HDC) in an effort to restore a cancer patient's blood and immune cell production capacity which is destroyed in this aggressive form of cancer treatment. Conventional grafts from bone marrow or peripheral blood carry the risk that tumor cells will be given back to the patient along with the desired stem cells.

In transplantation with cell selection, a patient's stem cells are isolated from their blood, thereby substantially reducing tumor cells in the graft. This may reduce the chances of cancer relapse potentially caused by these cells and produce a better long-term outcome.

Improvements in transplantation techniques, including the wider use of cell selection, have also contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation.

As a result, HDC with transplantation has grown at an average annual rate of 21 percent over the past 10 years. Although still under study in high risk or metastatic breast cancer, HDC with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkins lymphoma.

Within the clinical transplant community, increasing adoption of cell selection to improve graft purity is expected to drive even more dramatic growth in selection procedures. In 1998 there were approximately 6,000 selections performed worldwide; by 2002 this number may exceed 30,000.

"Transplant surgeons and clinical oncologists clearly understand the logic of stem cell selection because increasing the purity of the graft by eliminating tumor cells fits with their ultimate treatment goal: to achieve minimum residual disease in the patient," said L. William McIntosh, President of Nexell Therapeutics Inc. "Now that we can actively market the advantages of selection, we expect the number of selected transplant procedures to increase significantly over the next few years. In addition, we will promote the unique features of the Isolex(R), including full automation, cGMP processing, and closed system technology to significantly reduce potential contamination of the final stem cell product, that make it the best cell selection system in the world."

The Isolex(R) Magnetic Cell Selection Systems

The Isolex(R) 300 and Isolex(R) 300i are automated devices for the clinical separation of various types of cells from peripheral blood.

The Isolex(R) cell selection platform is versatile and can be used for a number of cell selection approaches, including the positive selection of a desired or target cell population from cell populations, such as tumor cells, that are potentially harmful to the patient.

The Isolex(R) 300i is fully automated, integrating all steps of the stem cell selection process into one continuous procedure that takes about 2.5 hours. The system uses a highly specific anti-CD34 stem cell antibody and paramagnetic beads to target and capture CD34+ stem cells.

The Isolex(R) 300i achieves high purity and yield of selected cells and its unique, patented stem cell release system leaves the selected cell surface virtually free of the antibodies and paramagnetic beads. Total automation of the sterile, closed-path procedure enhances consistency of the final cell product by greatly reducing the potential for contamination and errors in processing.

Thus the Isolex(R) 300i is ideally positioned to help cell processing laboratories meet the increasing level of regulatory and quality scrutiny to which they are being subjected.

The Isolex(R) cell selection systems are currently marketed in the European Union and Canada and are available for use in Hungary, Israel, New Zealand, Poland, and Slovenia. Nexell is seeking clearance to market the Isolex(R) systems in Australia, Japan and various countries in Eastern Europe and the Mediterranean region.

There are also a number of Isolex(R) systems currently in use in investigational protocols for gene therapy and dendritic cell therapy, engineered transplants with alternative donors and for autoimmune diseases, and depletion of specific T-cell subsets such as CD4 or CD8 cells.

Located in Irvine, California, Nexell Therapeutics Inc. (NASDAQ:NEXL), formerly VIMRX Pharmaceuticals Inc., is a cell therapy company whose mission is to put the power of the cell into the hands of healers. Nexell is developing and marketing innovative diagnostics and ex vivo cell therapies for cancer, autoimmune, metabolic and genetic diseases.

Nexell's lead product is the Isolex(R) Magnetic Cell Selection System. In addition, Nexell markets an extensive line of cell therapy preparation, storage and expansion products including the Cryocyte(TM) and Lifecell(R) brands.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations.

Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of the Company's clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in the Company's periodic reports on Form 10-K and 10-Q, and any prospectus describing the Company's securities.

NOTE TO INVESTORS AND EDITORS: Nexell Therapeutics Inc. press releases are available on the Internet through www.nexellinc.com and through BusinessWire's web site at http://www.businesswire.com. The releases are also available at no charge through BusinessWire's fax-on-demand service at 800/411-8792.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 6, 1999
Words:1203
Previous Article:KeyBank, N.A. Selected for Credit Line to Midisoft Corporation.
Next Article:IBS Interactive Acquires Spencer Analysis, Inc.; Acquisition Expands Company's IT Consulting Services.
Topics:


Related Articles
Nexell Therapeutics Receives FDA Approvable Letter for Isolex 300 and 300i Cell Selection System.
Approval to Market Isolex-R Cell Selection Systems in Canada Received by Nexell Therapeutics, VIMRX's Majority-owned Subsidiary.
Vimrx Name Change to Nexell Therapeutics Approved At Annual Stockholders Meeting.
Nexell and Baxter Complete Transfer Agreements; Sales and Distribution Changes Optimize Growth Potential for Isolex Magnetic Cell Selection Systems.
Nexell Therapeutics Launches Next Generation Isolex 300i Stem Cell Selection System in Europe; Version 2.5CE Sets New European Standard for Operation...
Nexell Therapeutics Receives FDA Approval On Next Generation Isolex 300i System; Version 2.5 for Positive Stem Cell Selection Delivers Enhanced...
Nexell Therapeutics Receives Approval to Market Isolex 300i System in Australia; Isolex 300i is the First Cell Selection Instrument to Meet TGA...
TRANSITION TO BEGIN ISLET NEOGENESIS U.K. PHASE I TRIAL.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters